A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

  • End date
    Oct 31, 2025
  • participants needed
  • sponsor
    Bristol-Myers Squibb
Updated on 25 October 2022


The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.

Condition Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
Treatment Nivolumab, Relatlimab
Clinical Study IdentifierNCT04567615
SponsorBristol-Myers Squibb
Last Modified on25 October 2022


Yes No Not Sure

Inclusion Criteria

Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
Must have advanced/metastatic HCC
Have to be immunotherapy treatment-naive in the advanced/metastatic setting
Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion
Child-Pugh score of 5 or 6
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 for ECOG performance status scale

Exclusion Criteria

Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
Prior organ allograft or allogeneic bone marrow transplantation
No uncontrolled or significant cardiovascular disease
No active known autoimmune disease
Other protocol-defined inclusion/exclusion criteria apply
Have received one or two lines of tyrosine kinase inhibitor therapies
Evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note